[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"corneal-diseases\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:corneal-diseases":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,6,0,[8,41,74,103,122,146],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":15,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":22,"conditions":23,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":30,"startDateStruct":33,"completionDateStruct":35,"leadSponsor":37,"locationsCount":40},"100604455","data-gathering-for-a10900-100604455",false,"NCT07149740","Data Gathering for A10900","Inclusion\u002FExclusion Criteria Inclusion Criteria for Retinal Disease Group\n\n1. Participants 22 years of age or older on the date of informed consent\n2. Participants able to understand the written informed consent and willing to participate as evidenced by signing the informed consent\n3. BCVA 20\u002F400 or better in the study eye\n4. Participants presenting at the site with retinal disease\n5. Diagnosis of some type of retinal pathology by investigator, may include, but not limited to: Macular Degeneration (including participants with drusen and geographic atrophy and choroidal neovascularization), Diabetic Macular Edema, Diabetic Retinopathy, Macular Hole, Epiretinal Membrane, Central Serous Retinopathy and others\n\nExclusion Criteria for Retinal Disease Group\n\n1. Participants unable to tolerate ophthalmic imaging\n2. Participants not able to obtain acceptable OCT images due to ocular media opacity or other reasons\n3. Participant has a condition or is in a situation which the investigator feels may put the participant at significant risk, may confound the study results, or may interfere significantly with the participant's participation in the study\n4. Presence of glaucoma or any ocular pathology other than a retinal pathology in the study eye as determined by self-report and\u002For investigator assessment at the study visit;\n\nInclusion Criteria for Glaucoma Group\n\n1. Participants 22 years of age or older on the date of informed consent\n2. Participants able to understand the written informed consent and willing to participate as evidenced by signing the informed consent\n3. BCVA 20\u002F40 or better in the study eye\n4. History of Visual field defects within the previous year from the study visit or measured the day of the study visit consistent with glaucomatous optic nerve damage with at least one of the following two findings:\n\n   1. On pattern deviation (PD), there exists a cluster of 3 or more points in an expected location of the visual field depressed below the 5% level, at least 1 of which is depressed below the 1% level;\n   2. Glaucoma hemi-field test \"outside normal limits.\"\n5. Glaucomatous optic nerve damage as evidenced by any of the following optic disc or retinal nerve fiber layer structural abnormalities:\n\n   1. Diffuse thinning, focal narrowing, or notching of the neuroretinal rim, especially at the inferior or superior poles with or without disc hemorrhage;\n   2. Optic disc neural rim asymmetry of the two eyes consistent with loss of neural tissue\n\nExclusion Criteria for Glaucoma Group\n\n1. Participants unable to tolerate ophthalmic imaging\n2. Participants not able to obtain acceptable OCT images due to ocular media opacity or other reasons\n3. Participant has a condition or is in a situation which the investigator feels may put the participant at significant risk, may confound the study results, or may interfere significantly with the participant's participation in the study\n4. No reliable visual field test result within the previous year from the study visit, defined as fixation losses \\> 33% or false positives \\> 33%, or false negatives \\> 33% in the study eye\n5. Presence of any ocular pathology except glaucoma in the study eye Inclusion Criteria for Corneal Group\n\n1\\. Participants 22 years of age or older on the date of informed consent 2. Participants able to understand the written informed consent and willing to participate as evidenced by signing the informed consent 3. Participants presenting at the site with corneal disease, for example but not limited to, corneal disorders due to contact lens wear, post-refractive surgery, dry eye, keratoconus 4. Participant is able to comply with the study procedures.\n\nExclusion Criteria for Corneal Group\n\n1. Participants unable to tolerate ophthalmic imaging\n2. Participant has a condition or is in a situation which the investigator feels may put the participant at significant risk, may confound the study results, or may interfere significantly with the participant's participation in the study\n3. Participant with ocular media not sufficiently clear to obtain acceptable OCT images.\n\nInclusion Criteria for Normal Group\n\n1. Participants 22 years of age or older on the date of informed consent\n2. Participants able to understand the written informed consent and willing to participate as evidenced by signing the informed consent\n3. Participants presenting at the site with normal eyes (Cataracts, LASIK, PRK, and peripheral pathology that does not affect the posterior pole region, for example lattice and peripheral drusen, are allowed).\n4. BCVA 20\u002F40 or better (each eye)\n5. Participant is able to comply with the study procedures\n\nExclusion Criteria for Normal Group\n\n1. Participants unable to tolerate ophthalmic imaging\n2. Participant has a condition or is in a situation which the investigator feels may put the participant at significant risk, may confound the study results, or may interfere significantly with the participant's participation in the study\n3. Participant with ocular media not sufficiently clear to obtain acceptable OCT images\n4. History of leukemia, dementia or multiple sclerosis",true,"ALL","22 Years",{"count":19,"type":20},180,"ESTIMATED","OBSERVATIONAL","The objective of this study is to gather Optical Coherence Tomography (OCT) data on normal and diseased eyes",[24,25,26,27],"Retinal Disease","Healthy","Glaucoma","Corneal Diseases","RECRUITING","2026-02-11",{"date":31,"type":32},"2026-02-13","ACTUAL",{"date":34,"type":32},"2025-06-26",{"date":36,"type":20},"2026-05-01",{"name":38,"class":39},"Optos, PLC","INDUSTRY",4,{"id":42,"slug":43,"hasResults":11,"nctId":44,"briefTitle":45,"officialTitle":46,"acronym":47,"eligibilityCriteria":48,"healthyVolunteers":11,"sex":16,"minAge":49,"maxAge":4,"enrollmentInfo":50,"targetDuration":4,"studyType":52,"phases":53,"briefSummary":55,"conditions":56,"keywords":59,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":63,"lastUpdatePostDateStruct":64,"startDateStruct":66,"completionDateStruct":68,"leadSponsor":70,"locationsCount":73},"100594843","4d-duke-microscope-integrated-optical-coherence-tomography-in-a-zeiss-artevo-800-100594843","NCT07024719","4D Duke Microscope Integrated Optical Coherence Tomography in a Zeiss Artevo 800","First Use of Duke 4D Microscope Integrated OCT (MIOCT) Integrated Into Zeiss Artevo 800 Ophthalmic Surgical Microscope in the Operating Room","4D MIOCT","Inclusion Criteria:\n\n* Adult participants 18 years of age and older\n* Patients undergoing surgery for ocular disease\n* Adults able and willing to give informed consent to participate in the study\n\nExclusion Criteria:\n\n* Patients with any ocular disease that restricts the ability to perform OCT scanning","18 Years",{"count":51,"type":20},5,"INTERVENTIONAL",[54],"NA","The study team will conduct the first in-human pilot studies using 4D MIOCT for imaging in the operating room. Building on the earlier integration and wet-lab validations, the researchers will assess the system's ease of use, safety, and visualization of intended structures during various anterior and posterior segment ophthalmic procedures.",[27,57,58],"Retinal Diseases","Ocular Diseases",[60,61,62],"Microscope integrated OCT","intraoperative OCT","optical coherence tomography (OCT)","2026-01-14",{"date":65,"type":32},"2026-01-16",{"date":67,"type":32},"2025-07-24",{"date":69,"type":20},"2026-10",{"name":71,"class":72},"Duke University","OTHER",1,{"id":75,"slug":76,"hasResults":11,"nctId":77,"briefTitle":78,"officialTitle":79,"acronym":4,"eligibilityCriteria":80,"healthyVolunteers":11,"sex":16,"minAge":81,"maxAge":4,"enrollmentInfo":82,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":84,"conditions":85,"keywords":88,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":94,"lastUpdatePostDateStruct":95,"startDateStruct":97,"completionDateStruct":99,"leadSponsor":101,"locationsCount":73},"100591686","validation-of-the-use-of-terahertz-scanning-system-on-corneal-scars-and-corneal-edema-100591686","NCT06983652","Validation of the Use of Terahertz Scanning System on Corneal Scars and Corneal Edema","Validation of the Use of Terahertz Scanning System on Corneal Scars and Corneal Edema: Phase II Clinical Trial","Inclusion Criteria:\n\n* Be at least 21 years of age.\n* Regardless of gender (Male\u002FFemale).\n* Regardless of race (Chinese\u002FMalay\u002FIndian\u002FEurasian\u002FOthers).\n* Willingness and ability to follow all instructions and comply with study schedule for study visit.\n* Patients with corneal endothelial dysfunction (Fuchs' endothelial dystrophy or other causes of bullous keratopathy) at any disease stage OR Patients with corneal scars from any cause, with the absence of corneal edema.\n* Ability to hold face sufficiently stable to undergo necessary scans.\n\nExclusion Criteria:\n\n* Eyes with active inflammation or infection, or chronic ocular surface inflammation\n* Unable to give consent\n* Physically immobile\u002Fpoor instructional compliance\n* PI determined\n* Pregnant\u002F breast feeding women","21 Years",{"count":83,"type":20},150,"This observational study aims to validate the use of THz scanning system in corneal edema and corneal scars, and to investigate the accuracy and performance on the use of THz scanning system in the evaluation of the progression of corneal edema and corneal scars. Participants corneal scars and corneal edema will undergo THz scanning, followed by a series of conventional clinical examinations for detailed characterization of the corneal lesion. The performance of the use of THz system on corneal scars and edema will be evaluated by correlating measurements from the THz scans with those obtained from standard clinical methods. The investigators hypothesize that the THz scanning system has the capacity to evaluate the hydration level on human corneas.",[27,86,87],"Corneal Scars and Opacities","Corneal Edema",[89,90,91,92,93],"cornea","corneal scar","corneal edema","Terahertz","hydration","2025-05-14",{"date":96,"type":32},"2025-05-21",{"date":98,"type":32},"2024-07-01",{"date":100,"type":20},"2026-08-31",{"name":102,"class":72},"Singapore Eye Research Institute",{"id":104,"slug":105,"hasResults":11,"nctId":106,"briefTitle":107,"officialTitle":108,"acronym":4,"eligibilityCriteria":109,"healthyVolunteers":11,"sex":16,"minAge":81,"maxAge":4,"enrollmentInfo":110,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":111,"conditions":112,"keywords":113,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":114,"lastUpdatePostDateStruct":115,"startDateStruct":117,"completionDateStruct":119,"leadSponsor":121,"locationsCount":73},"100590467","evaluation-of-the-safety-of-terahertz-scanning-system-on-corneas-100590467","NCT06967792","Evaluation of the Safety of Terahertz Scanning System on Corneas","Evaluation of the Safety of Terahertz Scanning System on Corneas: Phase I Trial","Inclusion Criteria:\n\n* Be at least 21 years of age\n* Regardless of gender (Male\u002FFemale)\n* Regardless of race (Chinese\u002FMalay\u002FIndian\u002FEurasian\u002FOthers)\n* Willingness and ability to follow all instructions and comply with study schedule for study visit\n* Have at least 1 eye (Study eye) that is deemed functionally blind but contain healthy corneas\n* Ability to hold face sufficiently stable to undergo necessary scans\n* Best Spectacle Corrected Visual Acuity (BSCVA) in the study eye of hand motion or worse\n\nExclusion Criteria:\n\n* Pregnant\u002FBreast-feeding women\n* Eyes with previous major surgery on the cornea such as corneal transplantation, refractive surgery, corneal cross-linking procedure\n* Eyes with previous infectious keratitis\n* Eyes with long-term use of glaucoma eye drops\n* Eyes with known moderate or server meibomian gland dysfunction\n* Eyes with active inflammation or infection, or chronic ocular surface inflammation\n* Systemic diseases that affect the ocular surface, such as systemic autoimmune diseases",{"count":51,"type":20},"This observational study aims to establish the safety profile of the use of Terahertz (THz) scanning system on corneal diseases. Participants with \"non-seeing\" eyes but normal corneas will undergo THz scanning. Eye examinations will be conducted at baseline, immediately after scanning, and at 1 day, 1 week, and 1 month post-scanning. These examinations will include measurements of visual acuity, eye structural, retinal health, corneal cell morphology, and corneal nerve status. The investigators hypothesize that the THz scanning system is safe for application to the human cornea.",[27],[89,91,92,93],"2025-05-13",{"date":116,"type":32},"2025-05-16",{"date":118,"type":32},"2024-04-01",{"date":120,"type":20},"2026-04-30",{"name":102,"class":72},{"id":123,"slug":124,"hasResults":11,"nctId":125,"briefTitle":126,"officialTitle":126,"acronym":4,"eligibilityCriteria":127,"healthyVolunteers":11,"sex":16,"minAge":128,"maxAge":129,"enrollmentInfo":130,"targetDuration":4,"studyType":52,"phases":132,"briefSummary":133,"conditions":134,"keywords":135,"overallStatus":137,"whyStopped":4,"lastUpdateSubmitDate":138,"lastUpdatePostDateStruct":139,"startDateStruct":141,"completionDateStruct":142,"leadSponsor":144,"locationsCount":4},"100585607","the-relation-between-bss-solution-temperature-and-endothelial-cells-and-post-phaco-discomfort-100585607","NCT06904560","The Relation Between BSS Solution Temperature and Endothelial Cells and Post Phaco Discomfort","Inclusion Criteria:\n\n* patients with cataract\n* more than 40 years\n* no glaucoma\n* no retinal abnormalities\n* no retinal abnormalities\n\nExclusion Criteria:\n\npatients with corneal diseases patients less than 40 patients with previous eye surgery","40 Years","80 Years",{"count":131,"type":20},40,[54],"patients underwent phacoemulsification , balanced saline solution used during the operation will be at room temperature in one group and cool 2.7 c in the other group. the patients will be followed for 3 months after phacoemulsification regarding corneal endothelial cells and anterior segment inflammatory signs",[27],[136],"cornea, cataract","NOT_YET_RECRUITING","2025-03-28",{"date":140,"type":32},"2025-04-01",{"date":140,"type":20},{"date":143,"type":20},"2025-07-01",{"name":145,"class":72},"Sohag University",{"id":147,"slug":148,"hasResults":11,"nctId":149,"briefTitle":150,"officialTitle":150,"acronym":151,"eligibilityCriteria":152,"healthyVolunteers":11,"sex":16,"minAge":49,"maxAge":4,"enrollmentInfo":153,"targetDuration":4,"studyType":52,"phases":155,"briefSummary":157,"conditions":158,"keywords":168,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":169,"lastUpdatePostDateStruct":170,"startDateStruct":172,"completionDateStruct":174,"leadSponsor":176,"locationsCount":73},"100550753","early-phase-1-novel-antisense-oligonucleotide-eye-drops-for-treating-antibiotic-resistant-bacterial-keratitis-100550753","NCT06451172","Novel Antisense Oligonucleotide Eye Drops for Treating Antibiotic-Resistant Bacterial Keratitis","ASOTARI","Inclusion Criteria:\n\n* The results of antimicrobial susceptibility testing in patients with bacterial keratitis showed multidrug-resistant bacterial infections, and the existing commercial antibiotics could not effectively control the disease.\n* Age over 18 years.\n* No systemic immune eye disease.\n* Good eyelid structure and blink function.\n* Exists the potential of visual recovery by evaluation of ocular structure and function.\n* Subjects or their legal guardians voluntarily participate in this study, sign informed consent, good compliance and cooperation with follow-up visits.\n\nExclusion Criteria:\n\n* Lacrimal coating and blink function loss.\n* Schirmer's test result is less than 2mm for severe dry eye disease.\n* Pregnant and lactating women (pregnancy defined in this study as positive urine pregnancy test).\n* Currently is involved in clinical trials of other drugs or medical devices.\n* Active eye infection (including but not limited to: blepharitis, infectious conjunctivitis, sclerotitis, endophthalmitis) in target eye or contralateral eye within 30 days prior to enrollment.\n* Ocular surface malignant tumor.\n* A history of allergic reaction or allergy to sodium luciferin, allergy to protein products used for treatment or diagnosis, allergy to ≥ 2 drugs or non-drug factors, or current allergic disease.\n* current in an infectious disease requiring oral, intramuscular or intravenous administration.\n* Patients with systemic immune diseases.\n* Any uncontrolled clinical problems (such as severe mental, neurological, cardiovascular, respiratory and other systemic diseases and malignant neoplasms).\n* Not effective contraception.\n* In uncontrolled hypertension, systolic is no less than 160 mmhg, diastolic is no less than 100 mmhg.\n* In uncontrolled diabetes, fasting glucose is no less than 10.0umol\u002FL.\n* Renal insufficiency, serum creatinine is more than 133umol\u002FL.\n* Arrhythmia, myocardial ischemia, myocardial infarction (diagnosed by electrocardiogram).\n* Liver dysfunction, al ANINE aminotransferase and aspartate aminotransferase levels are higher than 80 IU\u002FL.\n* Platelet level is below 100,000 \u002FuL or above 450,000 \u002FuL.\n* Hemoglobin level is below 10.0g\u002FdL (male) or 9.0g\u002FdL (female).\n* No anticoagulant was used, prothrombin time is higher than 16s, and thrombin time of activated part is higher than 50s.\n* HIV infection (HIV-positive).\n* Subjects lack compliance with the study or the ability to sign informed consent.\n* There are currently signs of systemic infection, including fever and ongoing antibiotic treatment (in this study, systemic infection was defined as deviation from normal values of white blood cells, lymphocytes, and neutrophils on routine blood tests).\n* Administration of Glucocorticoids and other systemic immunosuppressive drugs.\n* The investigator judges other conditions unsuitable for the trial",{"count":154,"type":20},20,[156],"EARLY_PHASE1","The purpose of this study is to evaluate the safety and efficacy of GP-asPNA for in vivo treatment of severe antibiotic resistant bacterial keratitis.",[159,160,161,27,162,163,164,165,166,167],"Bacterial Keratitis","Antibiotic-resistant Bacteria","Infections, Bacterial","Eye Diseases","Vision Disorders","Sensation Disorders","Blindness","Antisense Peptide Nucleic Acid","Antibacterial Therapy",[159,161,27,162],"2024-06-08",{"date":171,"type":32},"2024-06-11",{"date":173,"type":32},"2023-10-11",{"date":175,"type":20},"2026-10-31",{"name":177,"class":72},"Eye & ENT Hospital of Fudan University"]